- Home
- Publications
- Publication Search
- Publication Details
Title
Bendamustine for treatment of chronic lymphocytic leukemia
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 13, Issue 10, Pages 1495-1505
Publisher
Informa Healthcare
Online
2012-06-06
DOI
10.1517/14656566.2012.693163
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma
- (2010) Joel S. Owen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
- (2010) S. J. Lemery et al. CLINICAL CANCER RESEARCH
- Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma
- (2010) Trevor W. Dennie et al. CLINICAL THERAPEUTICS
- Bendamustine-Associated Hemolytic Anemia
- (2009) Lisa E Glance et al. ANNALS OF PHARMACOTHERAPY
- Bendamustine: Rebirth of an Old Drug
- (2009) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
- (2009) Wolfgang U. Knauf et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia
- (2009) Rudolf Weide et al. LEUKEMIA & LYMPHOMA
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
- (2008) L. M. Leoni et al. CLINICAL CANCER RESEARCH
- Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro
- (2008) M. Schmidt-Hieber et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
- (2008) Jonathan W. Friedberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
- (2008) K. Sue Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
- (2007) Sima Halevy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now